Vitamin A defi ciency has been reported to cause preneoplastic changes in the bronchial epithelium and to be associated with an increased risk of lung cancer ( 1 , 2 ) . Although results from initial clinical trials support a role for retinoids (natural and synthetic derivatives of vitamin A) in the chemoprevention of aerodigestive tract cancers ( 3 , 4 ) , data from randomized trials suggest that carotenoids or retinoids are not effective for lung cancer chemoprevention in the general population, although a benefi t may exist for nonsmokers ( 5 -8 ) . Clinical resistance to classical retinoids has been seen in lung cancer and is due, at least in part, to loss of retinoic acid receptors β (RAR β ) expression during lung carcinogenesis ( 9 -18 ) . Loss of RAR β expression is often caused by genomic loss or epigenetic silencing due to genomic methylation or histone deacetylation ( 11 , 19 ) . Hypermethylation of the RAR β promoter is an early event in lung carcinogenesis and is one of the most frequent methylation defects detected in the histopathologically normal bronchial epithelium of heavy smokers ( 20 ) . However, whether loss of RAR β 2 expression due to RAR β promoter methylation explains clinical resistance to RA is unknown.
We previously reported that all-trans -retinoic acid (RA) treatment can prevent in vitro transformation of immortalized human bronchial epithelial (HBE) cells and that this chemoprevention involves the proteasome-dependent degradation of G1 cyclins ( 21 , 22 ) . In a later study, we derived an RA-resistant HBE cell line (BEAS-2B-R1) by selecting RA-sensitive (BEAS-2B) HBE cells with increasing concentrations of RA. Unlike parental BEAS-2B cells, BEAS-2B-R1 cells treated with RA do not degrade cyclin D1 or cyclin E or undergo G 1 arrest ( 23 ) . RA treatment does not induce RAR β or RA target gene expression in these cells ( 23 , 24 ) .
In the present study, we used BEAS-2B-R1 RA-resistant HBE cells to investigate mechanisms responsible for RAR β silencing. We studied the methylation status of the RAR β P2 promoter, which is hypermethylated in certain lung cancer cells that lack RAR β 2 expression ( 11 ) . We then investigated whether treatment with the DNA demethylating agent azacitidine (also known as 5-azacytidine), alone or in combination with RA treatment, would restore RAR β expression and thereby induce the expression of previously identifi ed retinoid target genes in BEAS-2B-R1 cells. Also, we investigated the structure, expression, and function of RAR β 1 ′ , a previously unrecognized RAR β isoform, in lung cancer cells and in lung tumors and adjacent normal lung tissues.
M ATERIALS AND M ETHODS

Cell Culture
BEAS-2B and BEAS-2B-R1 cells were cultured in serumfree LHC-9 media in the dark at 37 °C with 5% CO 2 in a humidifi ed incubator as previously described ( 23 , 24 ) . H358, H441, and A549 lung cancer cell lines and COS African green monkey kidney fi broblast cells were obtained and passaged as recommended by American Type Culture Collection (Manassas, VA). H358, H441, and COS cell lines were cultured in RPMI media containing L -glutamine and 10% fetal bovine serum (FBS) supplemented with 100 IU/mL of penicillin and 100 μ g/mL of streptomycin. A549 cells were cultured in Ham's F12 media containing L -glutamine and 10% FBS supplemented with 100 IU/mL of penicillin and 100 μ g/mL of streptomycin.
Compounds and Treatments
RA and trichostatin A (Sigma Chemicals, St. Louis, MO) were prepared as 10 m M stock solutions in dimethyl sulfoxide (DMSO) and stored in liquid nitrogen. Azacitidine was obtained from the National Cancer Institute (Bethesda, MD) and dissolved in phosphate-buffered saline, pH 6.3. Trichostatin A treatment was performed at a dosage of 200 n M for 48 hours. Azacitidine treatment was performed at a dosage of 1 μ M for 48 hours.
Tumor Acquisition
Non -small-cell lung tumors and paired normal lung tissues were acquired as part of a Dartmouth-Hitchcock Medical Center Institutional Review Board (IRB) -approved tumor acquisition protocol. The banked tissues do not carry patient identifi ers and are exempt from IRB review under the Code of Federal Regulation Title 45, part 46.
Genomic DNA Methylation Sequencing
Genomic DNA was isolated from BEAS-2B and BEAS-2B-R1 cells using TRI Reagent (Molecular Research Center, Cincinnati, OH) per the manufacturer's protocol and was modifi ed with sodium bisulfi te, which converts unmethylated cytosine to uracil and amplifi ed by polymerase chain reaction (PCR) using established techniques and primers that are specifi c for bisulfi temodifi ed DNA: 5 ′ -AAGTGAGTTGTTTAGAGGTAGGAGGG-3 ′ (sense) and 5 ′ -CCTATAATTAATCCA AATAATCATTTACC-3 ′ (antisense) ( 11 ) . PCR products were then independently ligated into the TOPO-TA cloning vector (Invitrogen, Carlsbad, CA) using the manufacturer's protocol, transfected into One Shot competent cells (Invitrogen) per the manufacturer's protocol, selected on ampicillin-containing agarose plates, and individually expanded for analyses. Eight independent clones from each reaction were sequenced using established techniques ( 25 ) to assess the methylation frequency of each CG doublet in the RAR β P2 promoter, which has been identifi ed as hypermethylated in lung cancer cells that lack RAR β 2 expression. The genomic sequence of the region studied (nucleotides +106 to +250) is as follows: 5 ′ -CGAGAACGCGAGCGATCCGAG CAGGGTTTGTCTGG GCACCGTCGGGGTAGGATCCGGAACGCATTCGGAAGG C TTTTTGCAAGCATTTACTTGGAAGGAGAACTTGGGATCTT TCTGGGAACCCCCCGCCCCGGCTGGATTGGCC-3 ′ .
Protein Extraction and Immunoblot Analysis
Immunoblot analyses of extracts from the described experiments were performed using previously optimized techniques ( 23 ) . In brief, protein extracts were obtained by lysing cells in radioimmunoprecipitation assay buffer (10 m M Tris, 5 m M EDTA, 150 m M NaCl, 1% sodium deoxycholate, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 1 m M NaF, and 1 m M sodium orthovanadate) followed by centrifugation at 10 000 g for 15 minutes at 4 °C. The protein concentration of the supernatant was assayed using the Bradford method (Bio-Rad, Hercules, CA). Proteins were separated by sodium dodecyl sulfate -10% polyacrylamide gel electrophoresis and electrophoretically transferred to nitrocellulose membranes for immunoblot analyses as previously described ( 23 ) .
Primary antibodies to RAR β (rabbit polyclonal, 1 : 500), actin (goat polyclonal, 1 : 1000), placental transforming growth factor β (PTGF-β ; goat polyclonal, 1 : 500), and Fos-related antigen 1 (Fra-1; rabbit polyclonal, 1 : 500) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The transglutaminase II (TGase II; mouse monoclonal, 1 : 500) antibody was purchased from NeoMarkers (Fremont, CA). Species-appropriate mouse or rabbit (Amersham Biosciences Corporation, Piscataway, NJ) or goat (Santa Cruz Biotechnology) horseradish peroxidaseconjugated secondary antibodies were applied at a dilution of 1 : 3000 and binding was visualized using chemiluminescence (ECL Plus; Amersham Biosciences Corporation). Blocking peptide studies were performed for RAR β immunoblots of normal lung protein using a peptide specifi c to the C terminus of RAR β , per the manufacturer's protocol (Santa Cruz Biotechnology). The specifi city of the RAR β 1 ′ band was confi rmed by identifying the complete loss of the RAR β 1 ′ band in an immunoblot probed with the blocking peptide with the presence of the band in an immunoblot probed without blocking peptide performed simultaneously under otherwise identical conditions.
Reverse Transcription -PCR Amplifi cation of RAR β Isoforms
Total RNA was extracted from BEAS-2B cells, normal lung tissues, and malignant lung tissues using TRI Reagent (Molecular Research Center) per the manufacturer's protocol. RAR β isoforms were PCR amplifi ed with cDNA generated from 1 μ g of total RNA from each sample using the First-Strand cDNA synthesis system (Invitrogen) per the manufacturer's protocol. Annealing temperatures for the reactions were optimized for each primer pair. First-round amplifi cation was performed for 35 cycles. Nested amplifi cation was performed for 10 cycles using 5 μ L of the fi rst-round PCR product. Primers used to amplify RAR β isoforms were as follows: RAR β 1, 5 ′ -TGACGTCAGCAGTGAC TACTG-3 ′ (sense) and 5 ′ -GTGGTTGAACTGCACATTCAGA-3 ′ (antisense); RAR β 2 and RAR β 4, 5 ′ -AACGCGAGCGATCC GAGCAG-3 ′ (sense) and 5 ′ -ATTTGTCCTGGCAGACGAAG CA-3 ′ (antisense); and RAR β 1 ′ , 5 ′ -ATGAGGAATGAAGCTGA GTAGA-3 ′ (sense) and 5 ′ -ATTTGTCCTGGCAGACGAA GCA-3 ′ (antisense) ( 26 ) .
′ Rapid Amplifi cation of cDNA Ends PCR
RACE-Ready cDNA from human lung was purchased from Invitrogen. Two primers complementary to the fourth exon of RAR β were designed for nested 5 ′ rapid amplifi cation of cDNA ends (5 ′ -RACE) PCR amplifi cation of RAR β isoforms: fi rstround primer 5 ′ -ACTTGGTGG CCAGTTCACTGAATTTGT-3 ′ and second-round primer 5 ′ -CCTGGCAGACGAAGCAGGG TTTGTA-3 ′ . RACE products were cloned using the TOPO-TA vector (Invitrogen) and were sequenced as described previously ( 25 ) . One of the products identifi ed was a novel RAR β isoform, designated RAR β 1 ′ , which was registered as GenBank accession number DQ083391 .
Luciferase Assay
The cloned products from the 5 ′ -RACE PCR amplifi cation were digested with Eco RI and Xho I restriction endonucleases (New England Biolabs, Beverly, MA) to release the exon 4 segment. An existing RAR β 2-pSG5 construct containing the full length RAR β 2 cDNA in the pSG5 expression vector was also digested with appropriate restriction endonucleases. The sizefractionated fragments were gel purifi ed and the 5 ′ portion of RAR β 1 ′ was ligated into a truncated 3 ′ portion of the RAR β -pSG5 segment at exon 4 using T4 DNA ligase (Invitrogen) forming an RAR β 1 ′ -pSG5 expression construct. Sequencing was performed on separate clones to confi rm the presence of the desired construct. COS kidney fi broblast cells and BEAS-2B-R1 cells were both cotransfected with the RAR β 1 ′ expression plasmid, the RAR β 2 expression plasmid, or empty vector, and with a retinoic acid response element -thymidine kinase (RARE-TK) fusion gene construct containing a fi refl y luciferase reporter gene, and a TK -Renilla luciferase reporter gene construct (as a control for transfection effi ciency) using the FuGENE transfection system (Roche Diagnostics, Basel, Switzerland) according to the manufacturer's protocol. All transfections were performed in quadruplicate. BEAS-2B-R1 cells were cultured without exogenous RA for 7 days before transfection. Cells were then treated with RA at various doses or with vehicle (DMSO) for 3 hours. Luciferase activity was determined using the Dual Luciferase Reporter System (Promega, Madison, WI). Firefl y luciferase measurements were normalized to Renilla luciferase measurements as a control for transfection effi ciency.
RAR β 1 ′ Transfection and Proliferation Assays
To investigate the function of RAR β 1 ′ , we cotransfected H358 lung cancer cells with a puromycin resistance expression vector (p-Pur, BD Biosciences, Mountain View, CA) and with either the RAR β 1 ′ expression vector or an insertless vector (pSG5). Cells were then treated with 2 μ g/mL of puromycin for 24 hours to select against untransfected H358 cells. After 7 days, cells were plated in 96-well plates at a density of 3 × 10 3 cells per well for proliferation assays. Cellular proliferation was measured using the CellTiter-Glo assay kit (Promega). Assays were performed in triplicate. Basal luminescence activity and an ATP standard curve were each determined. Cells were then treated with either 4 μ M of RA or with DMSO (vehicle) for 24 hours. Luminescence activity and an ATP standard curve were determined each day that the assay was performed. Growth rates were calculated by subtracting the basal ATP content from ATP content measured after RA or vehicle treatments, as described previously ( 25 ) . Growth rates were normalized to that of vehicle-treated cells.
Statistical Methods
Differences between groups of continuous variables were assessed using the two-sample t test. P <.05 (two-sided) was considered statistically signifi cant.
R ESULTS RAR β P2 Promoter Methylation and RA-Induced Expression of Target Genes
To determine the methylation status of the RAR β P2 promoter was different in RA-sensitive (BEAS-2B) and RA-resistant (BEAS-2B-R1) HBE cells, we assayed the CG-methylation pattern of the P2 promoter in each cell line using bisulfi te modifi cation and PCR sequencing. Independent determinations of the RAR β P2 promoter methylation pattern in BEAS-2B and BEAS-2B-R1 cells revealed that most CG doublets were methylated (in ≥ 50% of samples) in both cell lines. The CG doublets at the 3 ′ region of this promoter were more frequently methylated in BEAS-2B-R1 than in BEAS-2B cells ( Fig. 1 ) .
We previously showed that BEAS-2B-R1 cells do not express RAR β after RA treatment, whereas BEAS-2B cells do. To determine if RA-inducible RAR β expression could be restored to BEAS-2B-R1 cells by demethylation, BEAS-2B-R1 cells were treated with azacitidine, a demethylating agent, or with trichostatin A, a histone deacetylase inhibitor. Pretreatment with 1 μ M azacitidine for 48 hours restored RA-inducible RAR β expression ( Fig. 2 ), whereas pretreatment with 200 n M trichostatin A for 48 hours did not (data not shown). A second RAR β immunoreactive protein that migrated at 47 kDa was identifi ed in BEAS-2B cells but was repressed in BEAS-2B-R1 cells ( Fig. 2 ) . The expression of this protein was not induced by RA treatment, azacitidine treatment, or combined RA and azacitidine treatments. The expression of the other RAR β and RXR isoforms was similar in BEAS-2B-R1 and BEAS-2B cells (data not shown). Protein expression of several RA target genes that were previously identifi ed as being induced by RA in BEAS-2B cells but not in BEAS-2B-R1 cells were assessed after treatment with various combinations of RA and azacitidine or with vehicle. Azacitidine treatment restored the RA induction of PTGF β expression to BEAS-2B-R1 cells but not RA-inducible expression of TGase II or Fra-1 ( Fig. 3 ) .
Identifi cation of a Novel RAR β Isoform
To identify the second RAR β protein repressed in BEAS-2B-R1 cells, we performed PCR analyses of RAR β 1, RAR β 2, and RAR β 4 using published techniques ( 26 ) . However, these RAR β isoforms were not amplifi ed from BEAS-2B cDNA. To investigate the possible existence of a novel RAR β isoform, we performed 5 ′ RACE -PCR analysis using RNA derived from normal human lung tissue. The fi rst round of PCR amplifi ed several dominant species ( Fig. 4, A ) , of which the largest species represented splice variants of RAR β 2 and the smallest represented a novel isoform of RAR β present in normal human lung. Reverse transcription -PCR analysis confi rmed the expression of this isoform in BEAS-2B cells (data not shown). This isoform contains an upstream exon spliced into exon 3 of RAR β with an in-frame start codon. This previously unrecognized RAR β isoform was designated as RAR β 1 ′ . The genomic structure of this isoform is shown in Fig. 4 , B .
Transient Transfection of BEAS-2B-R1 cells with RAR β 1 ′
Translation of RAR β 4 or RAR β 5 arising from a downstream start codon produces a low-molecular-weight RAR β protein that inhibits RA-induced transactivation of an RARE-containing reporter construct ( 27 , 28 ) . To determine whether the small novel RAR β 1 ′ also inhibits RA-inducible transactivation of RARE, we cotransfected BEAS-2B-R1 and COS cells with RAR β 1 ′ , RAR β 2, or empty vector and with a RARE-containing reporter gene construct. We then treated transfected cells with RA or DMSO (vehicle control). Cells transfected with RAR β 1 ′ or RAR β 2 had higher RA-induced activation of the RARE reporter construct transfected cells (mean = 3.2, 95% confi dence interval [CI] = 3.1 to 3.3, P <.001, and mean = 2.8, 95% CI = 2.6 to 3.0, P <.001, respectively) than vector-transfected cells (mean = 1.4, 95% CI = 1.3 to 1.5) ( Fig. 5 ) . A similar pattern of induction was observed in COS cells, although the basal reporter gene activity was not increased relative to vector transfectants in these cells, which Fra-1) , and transglutaminase II (TGase II) were performed in three independent experiments. Actin was used as a control for protein loading and transfer. Fig. 4 . Expression of RAR β 1 ′ in RNA derived form normal human lung tissue. A ) 5 ′ rapid amplifi cation of cDNA ends-labeled cDNA was subjected to polymerase chain reaction (PCR) amplifi cation using primers complementary to exon 4 of human RAR β . DNA sequence analyses of separate clones determined that the indicated largest species represent splice variants of RAR β 2 and the smallest species (680 bp) revealed a novel isoform containing an in-frame AUG start codon. The 100-bp size ladder is shown at right. B ) Genomic structure of the 5 ′ regions of RAR β 2, RAR β 4, and the novel isoform, RAR β 1 ′ . Arrows mark the initiation of transcription.
were cultured without exogenous RA (data not shown), unlike BEAS-2B-R1 cells, which were grown in media supplemented with RA ( 23 ) .
RAR β 1 ′ Expression in Lung Cancer Cell Lines and in Paired Normal and Malignant Lung Tissues
The relative expression of RAR β 1 ′ in lung cancers was sought using lung cancer cell lines as well as paired normal and malignant lung tissues. The RA response of several lung cancer cell lines was assessed by determining growth response following 4 μ M RA treatment for 72 hours. The patterns of RAR β 1 ′ and RAR β 2 expression in these cells, as determined by immunoblot analyses, were compared with those in RA-responsive BEAS-2B HBE cells. RAR β 2 protein was abundantly expressed in A549 cells and barely detected in untreated H358 and H441 cells ( Fig. 6, A ) . By contrast, RAR β 1 ′ protein expression was substantially lower in all three lung cancer cell lines than in BEAS-2B HBE cells ( Fig. 6, A ) . Furthermore, when three sets of paired malignant and normal tissues were compared, RAR β 1 ′ protein expression in de novo lung cancers was consistently lower than that of normal lung tissues ( Fig. 6, B ) . The identity of this protein was confi rmed with a blocking peptide specifi c for the C terminus of RAR β (data not shown). Another set of paired malignant and normal lung tissue with available RNA was subjected to reverse transcription -PCR analysis, from which RAR β 1 ′ RNA was detected in the normal lung tissue but not in the paired malignant tissue (data not shown).
Growth Suppression in RA-resistant Lung Cancer Cells Transfected with RAR β 1 ′
We then studied the functional consequences of restoring RAR β 1 ′ expression in lung cancer cells. RA treatment slightly increased expression of RAR β 2 and strongly increased that of the RA target gene PTGF-β in H358 cells ( Fig. 7, A ) . To determine whether exogenous RAR β 1 ′ expression in RA-resistant Normalized Luciferase Activity * * Fig. 6 . Expression of RAR β immunoreactive proteins in lung cancer cell lines and lung cancers and paired normal lung tissue. A ) Total protein was independently isolated from untreated BEAS-2B (RA sensitive) cells and from A549, H358, and H441 (RA resistant) cells and was subjected to immunoblot analyses for RAR β expression using a polyclonal antibody directed against the C terminus of RAR β that recognizes all RAR β isoforms. B ) Proteins isolated from paired normal (N) and malignant (T) lung tissues from three patients (cases). cells would restore the growth-suppressive effects of RA treatment, we stably transfected H358 cells with either RAR β 1 ′ -pSG5 or an empty expression vector (pSG5) as a control. Transfected cells were then treated with RA or vehicle for 24 hours. RA treatment at 4 and 8 μ M dosages had no effect on the growth of control cells ( Fig. 7, B ) . In RAR β 1 ′ transfected cells, by contrast, RA treatment suppressed growth (4 μ M : treated mean = 0.49 versus untreated mean = 1.0, difference = 0.51, 95% CI on the difference = 0.35 to 0.67, P = .003; 8 μ M : treated mean = 0.50 versus untreated mean = 1.0, difference = 0.50, 95% CI on the difference = 0.26 to 0.74, P = .015; Fig. 7, B ) . Engineered expression of RAR β 1 ′ in H358 cells was also associated with restored RA induction of the RA target gene, TGase II ( Fig. 7, C ) . By image quantifi cation, TGase II expression was 2.4-fold greater in RAtreated RAR β 1 ′ -transfected cells than that in RA-treated control vector-transfected cells.
D ISCUSSION
By investigating an RA-resistant HBE cell line BEAS-2B-R1 (derived by treating with increasing concentrations of RA), we have identifi ed the existence of a novel RAR β isoform, RAR β 1 ′ . This isoform was expressed in normal lung and in RA-sensitive BEAS-2B cells but not in RA-resistant BEAS-2B-R1 cells, lung cancer cell lines, or clinical lung cancers. Transfection of this isoform into an RA-resistant lung cancer cell line, H358, that expresses low levels of RAR β 2 conferred RA target gene induction and growth suppression following RA treatment. Thus, RAR β 1 ′ has distinct biologic properties compared with RAR β 2 and appears to function as a tumor suppressor in lung carcinogenesis.
Repression of RAR β is often observed in lung carcinogenesis and likely confers resistance to the growth-suppressive effects of vitamin A and its derivatives ( 9 -20 ) . In this study, a specifi c domain of the RAR β P2 promoter was found to be hypermethylated in RA-resistant HBE cells that in turn led to RAR β silencing. This region of the P2 promoter appears to serve a key role in methylation-mediated silencing of RAR β in the lung. Consistent with this hypothesis, a murine model of tobacco-induced lung carcinogenesis highlighted a similar region of promoter methylation that conferred RAR β silencing ( 16 ) .
In this study, we observed not only that RAR β 2 and RAR β 1 ′ have distinct functions but also that their expression is regulated differentially. Although neither RAR β 2 nor RAR β 1 ′ was expressed in RA-resistant BEAS-2B-R1 HBE cells, pretreatment with azacitidine restored only RA-dependent RAR β 2 expression but not expression of RAR β 1 ′ . This increased RAR β 2 expression was accompanied by increased expression of only one of the other RA target genes assayed, PTGF-β . Thus, we hypothesized that RAR β 1 ′ is required for the effi cient induction of those RA target genes that were not restored by azacitidine treatment alone or by combined RA and azacitidine treatments. In support of this view, cotransfection of BEAS-2B-R1 cells with RAR β 1 ′ and an RA-responsive reporter gene enhanced retinoid trans-activation of the RARE reporter construct. Also, exogenous expression of RAR β 1 ′ in the H358 RA-resistant lung cancer cell line, which only slightly increases expression of RAR β 2 following RA treatment, led to RA-dependent growth suppression and RA target gene induction, whereas no growth suppression was observed in H358 cells after RA treatment. These results strongly suggest that RAR β 1 ′ has a critical role in retinoid signaling in lung carcinogenesis. Furthermore, the observation that the expression of RAR β 1 ′ was repressed in BEAS-2B-R1 HBE and lung cancer cell lines and in lung cancer samples (but not in paired normal lung tissue) suggests that deregulation of this previously unrecognized RAR β isoform is important for conferring RA resistance. Restored expression of RAR β 1 ′ may only partially restore retinoid response. It is also possible that loss of RAR β 1 ′ expression will be necessary but not suffi cient for conferring retinoid resistance. Further understanding of the role of RAR β 1 ′ in response to retinoids would be gained by selective knockdown of RAR β 1 ′ .
Azacitidine treatment of RA-resistant HBE cells conferred RA-dependent induction of RAR β 2 expression and the activation of specifi c RA target genes. The results indicate that combining retinoids with a DNA demethylating agent might restore RAR β 2 expression to lung cancer cells ( 11 , 29 -31 ) . However, for an epigenetic targeting strategy to restore the full induction of RAR β target genes, the basis for RAR β 1 ′ repression needs to be determined. RAR β 1 ′ transcription is likely initiated by a distinct promoter near the fi rst exon of this isoform. We did not fi nd a classical RARE sequence in the promoter (data not shown), which is consistent with the inability of RA to induce RAR β 1 ′ expression ( Fig. 2 ) . Characterization of the RAR β 1 ′ promoter, regions of genomic DNA methylation, and histone acetylation changes within this region are the subject of future work. Combined treatment with a DNA demethylating agent and a histone deacetylase inhibitor might prove useful for restoring the expression and function of RAR β 1 ′ . For the success of this and other targeted approaches in lung cancer therapy, proof-of-principle studies are needed that confi rm whether pharmacologic mechanisms identifi ed in vitro are also engaged in the clinical setting ( 25 ) . In this regard, studies to investigate the benefi ts of combining retinoids with chromatin-modifying drugs should evaluate changes in specifi c retinoid receptor isoforms as well as their target genes that would directly confer retinoid biologic effects ( 24 ) .
This study is limited in part due to the number of cell lines studied. Future work will seek to extend our fi ndings by investigating the effects of RAR β 1 ′ expression in more cancer cell lines. Restored expression of RAR β 1 ′ may restore retinoid sensitivity only in certain cell contexts. Furthermore, selective knockdown of RAR β 1 ′ will be necessary to determine whether loss of this species is suffi cient to confer retinoid resistance.
Taken together, the data presented here directly implicate a critical role for RAR β 1 ′ in mediating retinoid biologic effects in the lung and perhaps other organ sites. RAR β 1 ′ itself could serve as a novel molecular pharmacologic target. The frequent repression of RAR β 1 ′ in lung carcinogenesis underscores its likely important biologic or clinical role. RAR β 1 ′ repression, despite RA treatment, offers a mechanistic explanation for clinical retinoid resistance that has been reported previously ( 7 , 8 ) . Identifi cation of pharmacologic approaches that restore RAR β 1 ′ expression would provide a basis for future retinoid-based combination strategies for lung cancer therapy or chemoprevention.
